Litcius/Paper detail

Kidney injury molecule-1 is a potential receptor for SARS-CoV-2

Chen Yang, Yu Zhang, Xia Zeng, Huijing Chen, Huijing Chen, Yuchen Chen, Dong Yang, Ziwei Shen, Xiaomu Wang, Xinran Liu, Mingrui Xiong, Hong Chen, Hong Chen, Kun Huang

2021Journal of Molecular Cell Biology69 citationsDOIOpen Access PDF

Abstract

COVID-19 patients present high incidence of kidney abnormalities, which are associated with poor prognosis and mortality. The identification of SARS-CoV-2 in the kidney of COVID-19 patients suggests renal tropism of SARS-CoV-2. However, whether there is a specific target of SARS-CoV-2 in the kidney remains unclear. Herein, by using in silico simulation, coimmunoprecipitation, fluorescence resonance energy transfer, fluorescein isothiocyanate labeling, and rational design of antagonist peptides, we demonstrate that kidney injury molecule-1 (KIM1), a molecule dramatically upregulated upon kidney injury, binds with the receptor-binding domain (RBD) of SARS-CoV-2 and facilitates its attachment to cell membrane, with the immunoglobulin variable Ig-like (Ig V) domain of KIM1 playing a key role in this recognition. The interaction between SARS-CoV-2 RBD and KIM1 is potently blockaded by a rationally designed KIM1-derived polypeptide AP2. In addition, our results also suggest interactions between KIM1 Ig V domain and the RBDs of SARS-CoV and MERS-CoV, pathogens of two severe infectious respiratory diseases. Together, these findings suggest KIM1 as a novel receptor for SARS-CoV-2 and other coronaviruses. We propose that KIM1 may thus mediate and exacerbate the renal infection of SARS-CoV-2 in a 'vicious cycle', and KIM1 could be further explored as a therapeutic target.

Topics & Concepts

KidneySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Acute kidney injuryTropismReceptorAntibodyBiologyVirologyChemistryImmunologyCoronavirus disease 2019 (COVID-19)MedicineVirusBiochemistryInternal medicineGeneticsDiseaseInfectious disease (medical specialty)Phagocytosis and Immune RegulationSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies